登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《HIV/AIDS抗病毒治疗手册》

  • 来源专题：艾滋病防治
  • 编译者： 李越
  • 发布时间：2005-01-26
  • 目前在全世界范围内仍缺乏根治HIV 感染的有效药物，临床上多采用综合治疗：即抗HIV 治疗、预防和治疗机会性感染、增加机体免疫功能、支持疗法及心理咨询。其中以抗病毒治疗最为关键。抗病毒治疗可能取得的效果是：最大程度的抑制病毒复制，重建机体免疫功能，提高感染者生活质量，从而降低与减少与HIV 相关疾病的发生率和死亡率。
  • 原文来源：http://www.chain.net.cn/admin/file/20040715152801.pdf
42浏览量
原文链接
相关报告

  • 《高效抗病毒治疗期间病毒峰值的动力学》
    • 来源专题：艾滋病防治
    • 编译者：李越
    • 发布时间：2005-04-16
    • Although intermittent episodes of low-level viremia are often observed in well-suppressed highly active antiretroviral therapy (HAART)-treated patients, the timing and amplitude of viral blips have never been examined in detail. We analyze here the dynamics of viral blips, i.e., plasma VL measurements of >50 copies/ml, in 123 HAART-treated patients monitored for a mean of 2.6 years (range, 5 months to 5.3 years). The mean (± the standard deviation) blip frequency was 0.09 ± 0.11/sample, with about one-third of patients showing no viral blips. The mean viral blip amplitude was 158 ± 132 human immunodeficiency virus type 1 (HIV-1) RNA copies/ml. Analysis of the blip frequency and amplitude distributions suggest that two blips less than 22 days apart have a significant chance of being part of the same episode of viremia. The data are consistent with a hypothetical model in which each episode of viremia consists of a phase of VL rise, followed by two-phase exponential decay. Thus, the term “viral blip” may be a misnomer, since viral replication appears to be occurring over an extended period. Neither the frequency nor the amplitude of viral blips increases with longer periods of observation, but the frequency is inversely correlated with the CD4+-T-cell count at the start of therapy, suggesting that host-specific factors but not treatment fatigue are determinants of blip frequency.
    123浏览量
    原文链接

  • 《HBV/HIV重叠感染的抗病毒治疗》
    • 来源专题：艾滋病防治
    • 编译者：李越
    • 发布时间：2011-11-07
    • 随着人类免疫缺陷病毒(human immunodeficiency virus,HIV)感染率快速增长,乙型肝炎病毒(hepatitis B virus,HBV)/HIV重叠感染成为一种临床易见疾病.HBV/HIV重叠感染使HBV和HIV的生物学行为发生改变,进而相互影响病情进展,使得HBV/HIV重叠感染患者的抗病毒治疗更为复杂.干扰素治疗HBV/HIV重叠感染患者HBeAg血清学转换发生率<10%,一般只用于可能发生血清学转换的患者.阿德福韦酯(ADV)无抗HIV活性,也不诱导HIV耐药,可用于不需高效抗逆转录病毒疗法(HAART)的患者.拉米夫定(LAM)、恩曲他滨(FTC)、替诺福韦(TDF)和恩替卡韦(ETV)对HBV和HIV都具有活性,用于两者都需要治疗时组成HAART,首选包括TDF+LAM或TDF+FTC的HAART方案,如果LAM/FTC耐药,可以加用或换用ETV或ADV挽救治疗.替比夫定(LdT)虽无抗HIV活性,但可以选择rtM204I耐药,不单独用于HBV/HIV重叠感染患者抗HBV治疗.
    59浏览量
    原文链接